LMIT (Lymphocyte Membrane Immunotherapy) aims to help improve fertility by modulating the immune system. It is particularly used for couples facing challenges such as recurrent miscarriages, implantation failure, or unexplained infertility, often linked to immune system dysfunction. LMIT involves using the male partner’s white blood cells (lymphocytes) to help regulate the female partner’s immune response, making the body more receptive to pregnancy.

The process typically includes an initial series of injections followed by periodic boosters to maintain immune balance throughout the fertility journey and early pregnancy.

LMIT (Lymphocyte Membrane Immunotherapy) works by modulating the immune system to enhance fertility and improve pregnancy outcomes. The treatment focuses on immune tolerance, which is important for a successful pregnancy.

1. Collection of Male White Blood Cells: The male partner's white blood cells (lymphocytes) are collected and processed in the lab. These cells are used to help regulate the female partner’s immune system.

2. Immune System Modulation: The processed lymphocytes are then injected into the female partner, typically over a series of treatments. This helps to reduce immune rejection and promotes better immune tolerance for the embryo.

3. Improved Pregnancy Environment: By balancing the immune system, LMIT, along with immunosuppression therapy, aims to lower the risk of immune-related pregnancy issues, such as recurrent miscarriages or implantation failure. The goal is to create a more receptive environment in the uterus, allowing for successful implantation and reducing the likelihood of immune system attacks on the developing embryo.

Overall, LMIT is designed to improve immune balance, reducing the body's potential immune responses that might interfere with pregnancy, and supporting a healthier conception process.

Please see our How it Works page for more information.

LMIT may be considered for couples experiencing recurrent miscarriages, repeated implantation failure, or unexplained infertility. It is particularly explored in cases where partners share specific genetic markers, such as the DQ Alpha Gene, which may contribute to challenges in conception or pregnancy maintenance.

The DQ Alpha gene relates to how your immune system recognises your partner’s genetic material. In some couples, certain combinations can result in immune-based implantation failure or miscarriage. LMIT aims to support tolerance in these cases by modulating immune responses.

Immunosuppression therapy is often used alongside LMIT to suppress overactive immune responses that may interfere with pregnancy. This can include conditions like elevated natural killer (NK) cell activity or the presence of antiphospholipid antibodies, both of which can cause immune-related pregnancy loss. Together, LMIT and immunosuppression therapy work to reduce immune system barriers, making the uterine environment more conducive to embryo implantation and pregnancy success.

Unlike many fertility treatments that focus on hormonal factors or assistive technologies like IVF, LMIT (Lymphocyte Membrane Immunotherapy) specifically targets immune-related factors that can impact fertility and pregnancy outcomes. It works by modulating the immune system to reduce the risk of immune rejection, which can contribute to issues like recurrent miscarriages, implantation failure, or unexplained infertility.

LMIT is considered an adjuvant therapy designed to enhance the chances of successful conception, particularly when immune system dysfunction is suspected. It is typically used under the guidance of a fertility specialist, who will assess whether this approach is suitable for your individual needs and circumstances.